Crescent Grove Advisors LLC Has $248,000 Stock Holdings in Pfizer Inc. (NYSE:PFE)

Crescent Grove Advisors LLC decreased its position in Pfizer Inc. (NYSE:PFE – Free Report) by 44.7% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 8,860 shares of the biopharmaceutical company’s stock after selling 7,160 shares during the period. Crescent Grove Advisors LLC’s holdings in Pfizer were worth $248,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Wellington Management Group LLP grew its holdings in shares of Pfizer by 4.9% during the fourth quarter. Wellington Management Group LLP now owns 239,209,768 shares of the biopharmaceutical company’s stock worth $6,886,849,000 after buying an additional 11,099,024 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in Pfizer by 8.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 104,246,432 shares of the biopharmaceutical company’s stock worth $2,985,783,000 after acquiring an additional 8,473,686 shares during the last quarter. Norges Bank bought a new position in shares of Pfizer during the 4th quarter worth approximately $2,129,927,000. Massachusetts Financial Services Co. MA raised its holdings in shares of Pfizer by 13.8% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 68,506,441 shares of the biopharmaceutical company’s stock valued at $1,972,300,000 after purchasing an additional 8,298,920 shares during the last quarter. Finally, Van ECK Associates Corp lifted its position in shares of Pfizer by 21.8% in the first quarter. Van ECK Associates Corp now owns 15,813,328 shares of the biopharmaceutical company’s stock worth $438,820,000 after purchasing an additional 2,829,178 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Pfizer stock traded up $0.12 during mid-day trading on Wednesday, hitting $29.02. 16,719,696 shares of the company’s stock traded hands, compared to its average volume of 39,231,648. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $37.15. The stock has a market cap of $164.42 billion, a price-to-earnings ratio of -483.58, a P/E/G ratio of 1.00 and a beta of 0.69. The firm has a 50 day simple moving average of $28.80 and a two-hundred day simple moving average of $27.94. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60.

Pfizer (NYSE:PFE – Get Free Report) last announced its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. The business had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. Pfizer’s quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.67 EPS. On average, research analysts expect that Pfizer Inc. will post 2.68 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be issued a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 5.79%. The ex-dividend date is Friday, July 26th. Pfizer’s dividend payout ratio is -2,800.00%.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. Barclays raised their target price on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Morgan Stanley lifted their target price on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research report on Thursday, May 2nd. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and increased their price target for the company from $28.00 to $34.00 in a research report on Wednesday, August 7th. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Finally, StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Eight research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $34.54.

View Our Latest Stock Analysis on Pfizer

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women’s health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

See Also

Want to see what other hedge funds are holding PFE?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).

Receive News & Ratings for Pfizer Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.